- Tilray Brands reported an adjusted EBITDA of $27.6 million for the fourth quarter, surpassing the estimate of $23.2 million, despite a 6.3% year-on-year decrease.
- Cannabis revenue came in at $67.8 million, down 5.7% from the previous year, but exceeded expectations of $58.8 million.
- Distribution revenue increased by 13% year-on-year to $74.1 million, surpassing the estimate of $66.8 million.
- Beverage Alcohol revenue decreased by 14% year-on-year to $65.6 million, missing the estimate of $88.4 million.
- Wellness revenue rose by 8.8% year-on-year to $17.0 million, slightly above the estimate of $16.6 million.
- The company reported a negative free cash flow of $13.1 million, compared to a positive $28.3 million the previous year.
- Loss per share was $1.30, significantly more than last year’s loss per share of 4.0 cents, and higher than the expected loss per share of 3 cents.
- Cash and cash equivalents stood at $221.7 million, a 2.9% decrease from the previous year, below the estimated $227.2 million.
- For the fiscal year ending May 31, 2026, Tilray expects adjusted EBITDA to range between $62 million to $72 million, signaling a potential growth of 13% to 31% from 2025.
- Analyst ratings include 3 buys, 8 holds, and no sells.
A look at Tilray Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 5 | |
| Dividend | 1 | |
| Growth | 2 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
With a substantial Smartkarma Smart Score of 5 for value, Tilray Inc is seemingly positioned as a strong contender in the market. The company’s focus on pharmaceutical products, including cannabis-based medicines, showcases its commitment to innovation and meeting the evolving needs of customers globally. This emphasis on creating value indicates a promising future for Tilray Inc, demonstrating its ability to provide products that are sought after and beneficial for consumers.
Although Tilray Inc may not have the highest scores in dividend, growth, resilience, or momentum, its overall outlook remains positive. With a balanced approach to factors such as growth and resilience, Tilray Inc is taking strategic steps towards securing a stable and successful future in the pharmaceutical industry. By leveraging its strengths in value creation, the company is well-positioned to navigate challenges and capitalize on opportunities ahead.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
